Abstract
18F-labeled 5-fluorouracil(FUra), 5-fluoro-2′-deoxyuridine(FdUrd), and 5-fluorouridine(FUrd) were synthesized with high radiochemical purities. The 18F-labeled pyrimidines were injected into rats. The metabolites in serum, bile, and urine were analyzed up to 2 h after administration by radio-high performance liquid chromatography(HPLC). The blood clearance of three pyrimidines was very rapid. In the serum the nucleosides and base disappeared very rapidly with a biological half-life of about 2 min and most of them had disappeared by 60 min. The metabolites in the urine were similar to those in the serum. In the bile pyrimidine nucleosides and base were not detected. 18F was found in the metabolites. Our results explain the high uptakes in the kidney and liver in biodistribution studies of the 18F-labeled pyrimidines.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abe Y, Fukuda H, Ishiwata K, Takahashi T, Yoshioka S, Yamada K, Endo S, Kubota K, Sato T, Matsuzawa T, Ido T (1983) Studies on 18F-labeled pyrimidines. Tumor uptakes of 18F-5-fluorouracil, 18F-5-fluorouridine, and 18F-5-fluorodeoxyuridine in animals. Eur J Nucl Med 8:258–261
Chaudhuri NK, Mukherjee KL, Heidelberger C (1958) Studies on fluorinated pyrimidines. VII. The degradative pathways. Biochem Pharmacol 1:328–341
Duschinsky R, Pleven E, Heidelberger C (1957) The synthesis of 5-fluoro-pyrimidines. J Am Chem Soc 79:4559–4560
Fowler JS, Finn RD, Lambrecht RM, Wolf AP (1973) The synthesis of 18F-5-fluorouracil. VII. J Nucl Med 14:63–64
Gallagher BM, Fowler JS, Gutterson NI, MacGregor RR, Wan C-N, Wolf AP (1978) Metabolic trapping as a principle of radiopharmaceutical design: Some factors responsible for the biodistribution of 18F-2-deoxy-2-fluoro-d-glucose. J Nucl Med 19:1154–1161
Heidelberger C (1982) Pyrimidine and pyrimidine nucleoside antimetabolites. In: Holland JF, Frei E III (eds) Cancer medicine, 2nd edn. Lea and Febiger, Philadelphia, pp 801–824
Mukherjee KJ, Heidelberger C (1960) Studies on fluorinated pyrimidines IX. The degradation of 5-fluorouracil-6-C14. J Biol Chem 235:433–437
Shani J, Wolf W, Schlesinger T, Atkins HL, Bradley-Moore PR, Casella V, Fowler JS, Greenberg D, Ido T, Lambrecht RM, MacGregor R, Mantesch C, Neirinckx R, Som P, Wolf AP, Wodinsky I, Meaney K (1978) Distribution of 18F-5-fluorouracil in tumor-bearing mice and rats. Int J Nucl Med Biol 5:19–28
Shani J, Young D, Schledinger T, Siemsen JK, Chlebowski RT, Bateman JR, Wolf W (1982) Dosimetry and preliminary human studies of 18F-5-fluorouracil. Int J Nucl Med Biol 9:25–35
Shiue CY, Fowler JS, Macgregor RR, Wolf AP (1979) The synthesis of F-18-5-fluorouridine (F-18-5-FUR) as a probe for measuring RNA synthesis and tumor growth rate in vivo. In: Radiopharmaceuticals II: Proceeding of the Second International Symposium on Radiopharmaceuticals, Society of Nuclear Medicine, New York, pp 259–264
Vine EN, Young D, Vine W, Wolf W (1979) An improved synthesis of 18F-5-fluorouracil. Int J Appl Radiat Isot 30:401–405
Author information
Authors and Affiliations
Additional information
Part I appeared in Eur J Nucl Med (1983) 8:258–261
Rights and permissions
About this article
Cite this article
Ishiwata, K., Ido, T., Kawashima, K. et al. Studies on 18F-labeled pyrimidines. Eur J Nucl Med 9, 185–189 (1984). https://doi.org/10.1007/BF00251469
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00251469